https://doi.org/10.4081/reumatismo.2025.1823
After what time interval are we justified to diagnose immune checkpoint inhibitor-mediated polymyalgia rheumatica?
Published: 3 March 2025
Abstract Views: 424
PDF: 46
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Dear Editor,
the number of cases of cancer patients diagnosed as having immune checkpoint inhibitor-mediated polymyalgia rheumatica has been steadily rising in published reports. However, the lack of a validated scale or algorithm is still a relevant methodological limit in diagnosing this nosologic entity...
Hysa E, Casabella A, Gotelli E, Campitiello R, Schenone C, Genova C, et al. Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms. Autoimmun Rev 2024; 23: 103589.
DOI: https://doi.org/10.1016/j.autrev.2024.103589
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, SchulzeKoops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis 2020; 80: 36-48.
DOI: https://doi.org/10.1136/annrheumdis-2020-217139
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reaction. Clin Pharmacol Ther 1981; 30: 239-45.
DOI: https://doi.org/10.1038/clpt.1981.154
Manzo C, Natale M, Isetta M, Castagna A. Comment on: immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Rheumatology 2025; 64: 900-1.
DOI: https://doi.org/10.1093/rheumatology/keae259
Manzo C, Isetta M. Back to the future: identification and classification of polymyalgia rheumatica and polymyalgia rheumatica-like syndromes following cancer immunotherapy with checkpoint inhibitors. Reumatologia 2021; 59: 62-3.
DOI: https://doi.org/10.5114/reum.2021.102600
How to Cite
Manzo, C., & Isetta, M. (2025). After what time interval are we justified to diagnose immune checkpoint inhibitor-mediated polymyalgia rheumatica?. Reumatismo. https://doi.org/10.4081/reumatismo.2025.1823
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- M. Varenna, D. Gatti, The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis , Reumatismo: Vol. 62 No. 3 (2010)
- G.P. Pasero, O. Di Munno, Analgesic dose range finding of lornoxicam compared to diclofenac. Crossover double blind study in rheumatoid arthritis , Reumatismo: Vol. 54 No. 3 (2002)
- L. Riente, The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis , Reumatismo: Vol. 56 No. s1 (2004)
- D.S. Meena, D. Kumar, G.K. Bohra, Acute severe gouty arthritis secondary to isotretinoin toxicity in a young male: a case report , Reumatismo: Vol. 75 No. 3 (2023)
- C. Manzo, Clinical practice guidelines for patients with polymyalgia rheumatica: the need for an active involvement of all stakeholder is still unmet , Reumatismo: Vol. 72 No. 2 (2020)
- A. Rebora, CONVENTIONAL THERAPIES FOR PSORIASIS , Reumatismo: Vol. 59 No. s1 (2007)
- V. Gerloni, I. Pontikaki, M Gattinara, F. Fantini, Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the litterature and personal experience , Reumatismo: Vol. 59 No. 3 (2007)
- M.A. Cimmino, Magnetic resonance imaging of the joints: a revolution for the practicing rheumatologist , Reumatismo: Vol. 60 No. 4 (2008)
- Eleonora Celletti, Giulio Gualdi, Emanuela Sabatini, Francesco Cipollone, Fabio Lobefaro, Paolo Amerio, Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review , Reumatismo: Early Access
- S. Barsotti, E. Cioffi, A. Tripoli, A. Tavoni, A. d’Ascanio, M. Mosca, R. Neri, The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature , Reumatismo: Vol. 70 No. 2 (2018)
<< < 2 3 4 5 6 7 8 9 10 11 > >>
You may also start an advanced similarity search for this article.
